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Background: Increased concentrations of exhaled nitric oxide (NO) have been detected in
inﬂammatory lung diseases including asthma and have been attributed to increased
expression and activity of inducible nitric oxide synthase (iNOS) within the airways.
However, previous studies of exhaled NO in patients with bronchiectasis have yielded
conﬂicting results, with reports of both increased and normal NO values. Recent evidence
from animal models suggests that chronic airway infection reduces NO production within
the lung, despite causing increased iNOS expression. We tested the hypothesis that, in
human subjects with bronchiectasis, chronic airway infection reduces NO output from the
conducting airways.
Methods: Using a recently described two-compartment model, we measured separately
the contributions of the conducting airways and the alveoli to exhaled NO in nine patients
with stable bronchiectasis and eight control subjects before and after inhaled
glucocorticoid therapy.
Results: We found that airway NO output was signiﬁcantly lower in bronchiectasis than in
normal airways whereas NO output from the alveoli was similar to that of control subjects.
High-dose inhaled glucocorticoid therapy did not alter airway or alveolar NO production.
Conclusions: These ﬁndings demonstrate that, in patients with bronchiectasis, airway NO
output is reduced and that iNOS does not contribute signiﬁcantly to airway NO production.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
S, inducible nitric oxide systhase; nNOS, neuronal nitric oxide synthase; CT, computerised tomography;
s supported by a grant from the Health Research Board, Ireland.
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Nitric oxide (NO) produced in the lungs can be detected in
exhaled gas from normal lungs and altered NO excretion
from the lungs has been reported in respiratory diseases.1,2
In particular, expression of the high output isoform of nitric
oxide synthase (iNOS or type II NOS) is increased in asthma3
and is associated with abnormally elevated NO concentra-
tions in exhaled gases.4,5 Exhaled NO may be reduced
towards normal by inhalation of selective inhibitors of iNOS
or glucocorticoids that can inhibit the expression of this
inducible isoform.6–8 Increased concentrations of exhaled
NO in association with increased expression of iNOS have
also been reported in several other lung diseases.9–11 Taken
together, these ﬁndings suggest that increased exhaled NO
in these diseased airways results from increased iNOS
activity in the airways. Other mechanisms that have been
postulated include increased airway diffusing capacity for
NO, altered neuronal NOS (nNOS) activity and altered pH of
airway lining ﬂuid.12–14 Thus, it has been suggested that
measurement of NO in exhaled air may be a useful non-
invasive index of inﬂammation in the respiratory tract in a
variety of inﬂammatory lung diseases.15
The airways of patients with bronchiectasis are chroni-
cally infected and inﬂamed and demonstrate increased
expression of iNOS,16 suggesting that exhaled NO should be
increased. However, studies in patients with bronchiectasis,
which have measured exhaled NO concentrations at a single
exhaled ﬂow rate, have yielded conﬂicting results with
reports of both elevated and normal values.16–20 Recent
reports of chronic airway infection in rodent models found
reduced NO production in the lung despite increased iNOS
expression.21–23
The previous conﬂicting reports of exhaled NO in
bronchiectasis, and the apparent discrepancy with rodent
studies, may have arisen because of the methods used for
measuring exhaled NO, in particular the ﬂow dependency of
these methods. More recently, a two-compartment model of
pulmonary NO output has been described which allows the
separate measurement of two ﬂow independent para-
meters, airway NO output and alveolar NO concentra-
tion.13,24–26 We undertook the present study to test the
hypothesis that chronic infection of the airways leads to a
reduction in NO output from the conducting airways, as
predicted by our previous studies in a rodent model.22,23
Using the two-compartment model described above, we
determined the separate contributions of NO output from
the conducting airways and from the gas exchange regions of
the lungs of bronchiectatic patients and compared them
with control subjects. In addition, we examined the effect
of inhaled corticosteroids on these two sources of NO. Some
of the results of these studies have been previously reported
in the form of an abstract.27
Methods
Recruitment of subjects
The study protocol was reviewed and approved by the Ethics
Committee of St. Vincent’s University Hospital and informed
written consent was obtained from all participating sub-jects. Patients with chronic, stable purulent bronchiectasis,
proven by CT scan were recruited from the outpatients
department of the hospital. Subjects were excluded if they
had a diagnosis of cystic ﬁbrosis, primary ciliary dyskinesia,
situs inversus, chronic bronchitis, atopy, asthma, paranasal
sinusitis, seasonal allergic disease, allergic bronchopulmon-
ary aspergillosis, a family history of bronchiectasis or other
lung disease. Other exclusion criteria were current treat-
ment with oral corticosteroids, evidence of Pseudomonas
aeruginosa in sputum (excluded by repeated sputum
culture), a respiratory tract infection in the 2 weeks
preceding recruitment, peripheral blood eosinophilia or
immunoglobulin deﬁciency.
The control subjects were healthy, non-smoking volun-
teers recruited from the hospital staff without history of any
chronic pulmonary disease, atopy, paranasal sinusitis, or
recent respiratory tract infection and who were not taking
any medications. They all had normal spirometry.
Study protocol
Baseline spirometry and exhaled NO were recorded in all
subjects on entry to the study. Those subjects with
bronchiectasis who were already taking prescribed inhaled
glucocorticoid medication prior to enrolment underwent a
two-week washout period before baseline measurements
were taken; other prescribed medications remained un-
changed. Following baseline measurements, all subjects
took a two-week course of inhaled ﬂuticasone (metered
dose inhaler, total dose 1000 mg twice daily) via a spacer
device. Pulmonary function testing and exhaled NO mea-
surements were then repeated.
Measurement of exhaled NO
Online exhaled NO measurements were made using a Sievers
280 chemiluminescence analyser (Sievers Instruments,
Boulder, CO, USA). The analyser was calibrated daily with
a known NO concentration (BOC gases, Dublin, Ireland) and
before each subject with NO-free air (Sievers zero-air-
ﬁlter). The sensitivity of the analyser to NO ranged fromo1
to 500,000 parts per billion (ppb) with a resolution of 1 ppb
and a response time of 200ms. Ambient NO waso3 ppb on
each day that measurements were taken.
Seated subjects inhaled maximally via their mouths to
total lung capacity, breath-held for 6–10 s and then exhaled
against a ﬁxed resistance, whilst maintaining a constant
mouth pressure; nose clips were not used. Mouth pressure
was maintained constant by means of a visual feedback
device. The manoeuvre was included for analysis if the
pressure was within 5% of the target value for a minimum of
6 s during exhalation while a stable concentration of NO was
observed during a plateau phase. The mean NO concentra-
tion of three adequately performed exhalations which were
within 5% of each other was taken to be the average NO
concentration at that ﬂow rate. Four exhaled ﬂow rates
(100, 150, 200 and 250ml/s) were examined in each subject
by using four ﬁxed resistances (Sievers, Boulder, CO, USA).
NO output was calculated as the product of steady-state NO
concentration and ﬂow rate, corrected to BTPS. A straight
line was ﬁtted to the plot of NO output against ﬂow by least
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airway NO output and the slope equalled alveolar NO
concentration.24
Reproducibility of exhaled NO measurements in healthy
controls
Reproducibility of exhaled NO measurements over the same
four ﬂow rates was previously conﬁrmed in group of 20
healthy female adults (age range 24–31 years) using the
same methodology. Subjects without history of atopy or
respiratory disease were recruited from among the staff and
medical students of the hospital. They had no history or
symptoms suggestive of asthma and pulmonary function
tests were normal. There was no overlap with the control
subjects from the bronchiectasis study. Exhaled NO mea-
surements were recorded in the morning on three occasions
at intervals of one week and reproducibility was conﬁrmed
by Bland–Altman analysis.28 The mean difference in airway
NO production measured on the ﬁrst and last occasions in a
single individual was 1.1 (15.6) nl/min. The limits of
agreement were 43.3 and 41.1. The mean difference in
alveolar NO concentration was 0.2 (2.4) ppb. The limits of
agreement were 4.5 and 4.9 in the Bland–Altman analysis.
The median alveolar NO concentrations on the ﬁrst and
last day were 1.6 (0.1–4.5) ppb and 1.2 (0.1–4.1) ppb,
respectively. The median airway NO output on the ﬁrst and
last day was 48.5 (27.4–87.2) nl/min and 54.2 (20.8–87.8)
nl/min, respectively.
Statistical analysis
Kolmogorov–Smirnov tests of normality were performed in
order to test the distributions of data prior to analysis. Both
alveolar NO and airway NO were normally distributed. The
values shown are means7standard deviations or medians
and ranges. Statistical comparisons are made using paired
and unpaired t-tests as appropriate. A p-value of less than
0.05 was accepted as statistically signiﬁcant.
Results
Subject characteristics
Twelve patients with bronchiectasis were recruited over an
eight month period. Three were subsequently excluded; one
due to non-compliance, one due to intercurrent lower
respiratory tract infection and one due to an inability toTable 1 Pulmonary function tests and dyspnoea score.
Bronchiectatics (n ¼ 9)
Pre-steroid Post-ste
FEV1, (L) 1.770.5 1.770
FVC, (L) 2.270.5 2.370
FEV1 (% pred) 70.0717.6 70.871
FVC, (% pred) 81.6710.9 82.471
FEV1/FVC (%) 73.4713.1 73.771
Values shown are means7standard deviation. Pre-steroid indicates v
indicates values recorded after a two-week course of inhaled steroidcorrectly perform the exhaled NO measurements. Nine
patients completed the study. All subjects were lifelong
non-smokers or ex-smokers for at least 1 year. The median
age (range) of the patient group was 54 (37–63) years and
they were all females. Four had developed bronchiectasis
secondary to severe childhood pneumonia, one from
documented childhood measles pneumonia and one due to
tuberculosis in young adulthood. Three cases were idio-
pathic. All were sputum producers of between one and two
eggcupfuls per day. The results of pulmonary function
testing and dyspnoea scores are shown in Table 1.
Six patients were taking prescribed inhaled steroids prior
to enrolment; these were withdrawn for a two-week period
prior to entry in accordance with the study protocol. Other
medications used to treat their airways disease included b-2
agonists and inhaled anticholinergics.
Eight control subjects were recruited. They had a median
age of 46 (33–55) years and a 7:1 female predominance.
Only subjects who complied with the inhaled steroid
medication for two weeks as assessed by interview and
change in canister weight were included. Figure 1 shows the
method of computing NO output in a sample control and
bronchiectatic subject.Exhaled NO measurements
Exhaled NO was measured in nine subjects with bronchiec-
tasis and eight age-matched controls. There was a linear
relationship between exhaled NO output and ﬂow rates
(Fig. 1) for all bronchiectasis patients (r2 ¼ 0.8170.17;
po0.001) and control subjects (r2 ¼ 0.8670.16; po0.001)
examined.
At baseline, mean airway NO production (Fig. 2a) was
31.8 (715) nl/min in subjects with bronchiectasis, signiﬁ-
cantly lower (po0.02) than in controls (52.5717.3 nl/min).
However, the mean alveolar NO concentration (Fig. 2b) in
the diseased group (2.572.0 ppb) did not differ signiﬁcantly
from the control group (2.471.6 ppb).
Following two weeks of inhaled steroids, mean airway NO
production was 36.1 (722.8) nl/min in the bronchiectasis
group and 58.6 (734.6) nl/min in the control group, neither
of which was signiﬁcantly different from the respective pre-
steroid values. Similarly, the mean alveolar NO concentra-
tion in the diseased group was 2.9 (71.6) ppb and in the
control group was 1.3 (71.4) ppb, neither of which had
changed signiﬁcantly from baseline values.Controls (n ¼ 8)
roid Pre-steroid Post-steroid
.5 3.170.5 3.270.5
.5 3.970.7 3.970.6
8.0 96.975.8 98.177.6
3.6 95.776.0 95.275.5
2.9 80.372.9 81.172.6
alues prior to a two-week course of inhaled steroid. Post-steroid
. % pred, percentage of predicted value.
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Figure 1 NO production plotted against four different ﬂow
rates prior to inhaled steroids in (a) control subject and (b) a
patient with bronchiectasis. The slope of the line equals the
alveolar NO concentration in parts per billion. The intercept of
the line equals the airway NO production in nl/min. VNO, nitric
oxide excretion. Flow, exhaled ﬂow rate.
S.C. Foley et al.1552Mean NO concentrations at all 4 ﬂow rates are shown in
Table 2. To allow comparison with previous studies, mean
exhaled NO concentrations at a ﬁxed ﬂow rate of 250ml/s
are presented in this table. There was no signiﬁcant
difference between bronchiectasis and controls at baseline,
in marked contrast to the signiﬁcantly lower values of
airway NO output observed in this study (Fig. 2a). Inhaled
steroid therapy did not signiﬁcantly alter exhaled NO
concentrations at 250ml/s in either group.
To allow for comparison with future studies,29 we report
mean NO output at a ﬂow rate of 50ml/s (Table 3). This ﬂow
rate corresponds to 3.0 l/min on the plots of ﬂow rate versus
NO output in Fig. 1. There was a signiﬁcant difference
between the two groups; prior to inhaled steroids, exhaled
NO output was statistically lower in the bronchiectatic group
compared to the control group (po0.05). Since exhaled NOconcentration at low ﬂow rates (50ml/s) is largely deter-
mined by NO output from the airways, this ﬁts very well with
our ﬁnding of reduced bronchial NO output in bronchiectasis
using the two-compartment model.Discussion
This is the ﬁrst study that reports the separate measure-
ments of airway NO output and alveolar NO concentration in
humans with chronic suppurative bronchiectasis not caused
by cystic ﬁbrosis. We were interested to separately measure
conducting airway NO output because this is a major site of
infection and inﬂammation in bronchiectasis. These data
show that airway NO output was decreased in bronchiectasis
compared to controls, while alveolar NO concentrations
were similar in both groups. We have also demonstrated that
inhaled steroids did not alter airway NO output in these
patients.
The standard approach in previous studies has been to
report NO concentration at a ﬁxed expiratory ﬂow rate
while nasal NO was excluded. However, this approach does
not provide information about the separate sources of the
NO in the lower airways. Moreover, the values observed are
dependant on the chosen ﬂow rate. More recent approaches
have provided additional important insights into the sites of
excretion of exhaled NO within the lungs. George and co-
workers ﬁrst described a two-compartment model in normal
subjects, an approach which others have subsequently found
to provide a good match with empirically derived data in
both normal subjects and those with respiratory dis-
ease.24–26,30–34 Using this two-compartment model, we were
able to separately measure airway NO output and alveolar
NO concentration in control subjects and in those with
chronic suppurative bronchiectasis. The values that we
observed in our normal subjects were similar to those
reported previously.35,36 In both our subject groups, there
was a linear relationship between exhaled NO output and
ﬂow rates (see Results section) suggesting that the two-
compartment model is applicable in this disease condition
(Fig. 1). This is in agreement with the reports of others in
both asthma and CF patients.13,33,34
Exhaled NO concentrations in bronchiectasis have pre-
viously been reported to be similar in control and
bronchiectatic subjects following measurement at a single
ﬁxed expiratory ﬂow rate of 250ml/s.18,19 For direct
comparison, we have reported our results in both groups
at this single ﬂow rate at baseline (Table 2) and we found
similar exhaled NO concentrations in control and bronch-
iectatic subjects. At this relatively high ﬂow rate, exhaled
NO is determined largely by the alveolar NO concentra-
tion.26 Thus, the similarity of exhaled NO concentrations at
this ﬂow rate in bronchiectatics and control subjects18,19 is
in good agreement with our ﬁnding that alveolar NO
concentrations were not signiﬁcantly different in these
two groups using the two-compartment model.
Kharitonov and colleagues have previously reported
increased exhaled NO concentrations in bronchiectasis17
in contrast to our ﬁndings and previous reports.18,19
However, peak rather than plateau expiratory NO concen-
trations were recorded in that study while subjects wore a
nose-clip. Differences in patient characteristics may also
ARTICLE IN PRESS
Table 3 NO output at 50ml/s calculated from 2-
compartment model plots.
Bronchiectasis
(n ¼ 9)
Controls
(n ¼ 8)
Pre-steroid (nl/min) 38.4717.1** 59.6719.1
Post-steroid (nl/min) 54.8718.6 68.8716.2
Values shown are means7standard deviations and ranges.
Pre-steroid indicates values prior to a course of inhaled
steroids. Post-steroid indicates values recorded after a two-
week course of inhaled steroid. NO output at 50ml/s is
reported in nl/min. **Po0.05 versus pre-steroid control
value.
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Figure. 2 Airway NO output (a) and alveolar NO concentrations (b) in control (n ¼ 8) and bronchiectatic (n ¼ 9) subjects prior to a
course of inhaled steroids. Mean values are indicated by the horizontal bars.
Table 2 Exhaled NO concentrations at four different expiratory ﬂow rates.
Expiratory ﬂow
rate (ml/s)
P-value Bronchiectasis (n ¼ 9) Controls (n ¼ 8)
Pre-steroid Post-steroid Pre-steroid Post-steroid
100 0.1 8.073.1 (3.8–13.7) 8.775.2 (3.5–20.2) 10.7 73.5 (5.7–15) 10.8 75.6 (5.6–19.5)
150 0.7 6.272.2 (3.2–9.5) 6.873.5 (2.8–9.6) 8.573.0 (4.7–11.9) 8.174.2 (4.2–12.6)
200 0.3 5.572.3 (2.4–9.5) 5.773.5 (3.7–8.8) 6.972.5 (3.7–10.6) 6.173.0 (3.2–10.8)
250 0.5 4.872.0 (2.2–8.7) 5.172.1 (3.0–7.9) 5.772.2 (2.6–9.1) 5.172.8 (2.4–9.8)
Values shown are means7standard deviations and ranges. Pre-steroid indicates values prior to a course of inhaled steroids. Post-
steroid indicates values recorded after a two-week course of inhaled steroid. NO concentrations are reported as parts per billion. P
values shown are for pre-steroid comparisons between both groups.
Airway NO output in bronchiectasis 1553have contributed to the differences in results. For this
reason, we carefully excluded all patients who might have
had an additional disease known to alter iNOS expression
and activity.Tsang et al.20 found no difference in exhaled NO
concentrations between bronchiectatic and control subjects
when measured at a single ﬂow rate of 50ml/s. Bronch-
iectasis patients with Pseudomonas infection had lower
levels of exhaled NO than their counterparts. We excluded
patients with pseudomonas infection from our study and by
measuring exhaled NO over a range of ﬂow rates we still
found a statistically signiﬁcant reduction in airway NO
output (but not in alveolar NO concentration) in bronch-
iectasis compared to controls. The discrepancy in results
may be contributed to by differences in methodology or by
the numerous exclusion criteria of our study.
Six patients with bronchiectasis underwent a two-week
washout period prior to enrolment in our study. It has been
shown that exhaled NO levels recover rapidly after cessation
of inhaled budesonide in mild asthmatics with complete
recovery of NO levels by the end of the ﬁrst week.37 Based
on this, a two-week washout period should have been
adequate to allow accurate baseline NO measurements to be
recorded at time of enrolment. It could be argued, however,
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increased baseline NO levels and consequently in a reduc-
tion in exhaled NO after inhalation of glucocorticoids. Our
ﬁndings that inhaled steroids have no signiﬁcant effect on
exhaled NO in subjects with bronchiectasis are consistent
with a recent report.38
iNOS expression is reported to be increased in the airways
of patients with bronchiectasis compared to controls.16
However, only three subjects with bronchiectasis were
analysed in that particular study. We and others have
previously reported in animal studies that chronic airway
infection leads to increased iNOS expression but not excess
NO production in intact lungs.21–23 A similar suppression of
iNOS activity may occur in chronic airway infection in
humans thus accounting for our present observation. An
alternative explanation is that NO production is increased
within the airway wall but not excreted into the airway
lumen due to increased local metabolism by superoxide
radicals in the presence of infection.39,40 This rapid
reaction, reducing NO to peroxynitrite, would prevent NO
reaching the airway lumen and reduce exhaled NO.41
However, we have recently shown in animal studies that
there was no evidence of augmented iNOS activity or
peroxynitrite production despite increased iNOS expres-
sion.23
Glucocorticoids inhibit the expression of iNOS but not that
of the constitutive NOS isoforms.42,43 Moreover, inhaled
glucocorticoids inhibit iNOS expression6–8 and reduce ex-
haled NO in asthma.7,44 If iNOS were a signiﬁcant contributor
to exhaled NO in bronchiectatic airways, then NO production
should be reduced after a course of inhaled steroid therapy.
We found no signiﬁcant change in airway NO production or
alveolar NO concentration in the bronchiectatic patients
after a two-week course of inhaled steroids, suggesting that
iNOS was not contributing to airway NO output in bronch-
iectasis. Our observation that inhaled steroids did not
decrease airway or alveolar NO production in normal
subjects is compatible with previous results.
Reduced airway NO could play a signiﬁcant role in the
pathogenesis of bronchiectasis. High concentrations of NO
may have an important anti-microbial role in airway defence
and loss of this action could facilitate chronic airway
infection, as has been suggested in cystic ﬁbrosis.45 Normal
airway NO production is required for sodium secretion by the
airway epithelium.45 Reduced NO leads to excessive sodium
reuptake by these cells, an action that could lead to
excessively viscid sputum, impaired sputum clearance and
thus susceptibility to chronic bacterial infection.45 Low NO
concentrations could also lead to lung damage through loss
of its anti-inﬂammatory function, which could contribute to
an excessive response to pulmonary infection resulting in
tissue damage. The extent to which these mechanisms
contribute to the pathogenesis of non-CF bronchiectasis
remains to be determined.
In conclusion, we have shown that, despite the previous
demonstrations of increased iNOS expression in bronchiec-
tasis, airway NO output was reduced in these patients. We
have also demonstrated that inhaled steroid did not further
reduce the airway NO which suggests that iNOS did not
contribute to exhaled NO in this disease. The reduced
airway NO output in bronchiectasis may contribute to the
pathogenesis of this disease.Acknowledgements
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